RA Capital Management Invests $10.6M in SAB Biotherapeutics Offering, Maintains 9.9% Stake
SABS has more than doubled off its 52-week low of $1.
Summary
RA Capital Management, a major institutional investor, purchased $10.6 million in pre-funded warrants as part of SAB Biotherapeutics' recent $85 million public offering, maintaining its 9.9% beneficial ownership.
Key Events · Ownership and Investor Activity · SABS
-
Significant Investment in Public Offering
RA Capital Healthcare Fund, L.P. purchased 2,753,246 pre-funded warrants for an aggregate of $10,599,721.78 in SAB Biotherapeutics' public offering on March 19, 2026.
-
Maintains 9.9% Beneficial Ownership
The investment allows RA Capital Management and its affiliates to maintain a 9.9% beneficial ownership stake in SAB Biotherapeutics, holding 7,311,225 shares.
-
Strategic Use of Pre-Funded Warrants
The pre-funded warrants have an exercise price of $0.0001 per share and include a 9.99% beneficial ownership blocker, preventing immediate conversion beyond this threshold.
Analysis · SABS · Life Sciences
RA Capital Management's significant $10.6 million investment in SAB Biotherapeutics' recent $85 million public offering, through the purchase of pre-funded warrants, signals strong institutional confidence. This participation, especially in a dilutive event, indicates a continued belief in the company's long-term prospects and strategic support from a major investor. The use of pre-funded warrants with a 9.99% beneficial ownership blocker allows RA Capital to maintain its significant stake without immediately triggering higher reporting thresholds, demonstrating a strategic approach to its investment.
At the time of this filing, SABS was trading at $3.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $200.2M. The 52-week trading range was $1.00 to $6.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.